
09/11/2025
Fresh this week: FDA proposes fast-track rules for ultra-rare drugs, + CDMO valuations are soaring.
• A new idea at FDA: you might get drug approval with just one strong study (single-arm) if it’s the only population you can study.
• A CDMO, Cambrex, is up for sale at $4B — showing pharma’s big move to bring manufacturing back to the U.S.
It’s a reminder: regulation and production are shifting fast. How do you see it affecting therapy access and supply?